Rani Therapeutics Holdings, Inc. (RANI) Financial Statements (2024 and earlier)

Company Profile

Business Address 2051 RINGWOOD AVENUE
SAN JOSE, CA 95131
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27,007117,453
Cash and cash equivalents27,007117,453
Restricted cash and investments 500 
Prepaid expense1,9422,142
Other undisclosed current assets71,475 
Total current assets:100,924119,595
Noncurrent Assets
Operating lease, right-of-use asset1,065 
Property, plant and equipment6,0384,612
Total noncurrent assets:7,1034,612
TOTAL ASSETS:108,027124,207
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,7562,514
Accounts payable1,4601,080
Accrued liabilities 2,2961,434
Debt  
Due to related parties53126
Other undisclosed current liabilities1,006 
Total current liabilities:4,8152,640
Noncurrent Liabilities
Long-term debt and lease obligation29,149 
Long-term debt, excluding current maturities29,149 
Liabilities, other than long-term debt59 
Operating lease, liability59 
Total noncurrent liabilities:29,208 
Total liabilities:34,0232,640
Equity
Equity, attributable to parent, including:36,85547,411
Additional paid in capital75,84255,737
Accumulated other comprehensive loss(73) 
Accumulated deficit(38,919)(8,331)
Other undisclosed equity, attributable to parent55
Equity, attributable to noncontrolling interest37,14974,156
Total equity:74,004121,567
TOTAL LIABILITIES AND EQUITY:108,027124,207

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Revenues  2,717
Gross profit:  2,717
Operating expenses(63,451)54,316
Other undisclosed operating loss  (108,632)
Operating loss:(63,451)(51,599)
Nonoperating income
(Investment Income, Nonoperating)
  89
Interest and debt expense(1,071)(1,166)
Loss from continuing operations before equity method investments, income taxes:(64,522)(52,676)
Other undisclosed income (loss) from continuing operations before income taxes1,248(371)
Loss from continuing operations before income taxes:(63,274)(53,047)
Income tax expense (benefit)(70)(41)
Loss from continuing operations:(63,344)(53,088)
Loss before gain (loss) on sale of properties:(53,088)
Net loss:(63,344)(53,088)
Net income attributable to noncontrolling interest32,75644,757
Net loss available to common stockholders, diluted:(30,588)(8,331)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(63,344)(53,088)
Other comprehensive income (loss)(149) 
Other undisclosed comprehensive loss  
Comprehensive loss:(63,493)(53,088)
Comprehensive income, net of tax, attributable to noncontrolling interest32,83244,757
Comprehensive loss, net of tax, attributable to parent:(30,661)(8,331)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: